UK MHRA Aims To Cast Early Access Scheme In New Light

Agency Wants To Make EAMS More Attractive To Sponsors Of Innovative Medicines

 
• By Vibha Sharma

The UK’s Early Access to Medicines Scheme continues to provide important flexibility, but companies also now have the option of a new ambitious pathway launched this year for accelerating time to market for innovative medicines.

A group of paper airplanes, one plane is flying in the other direction
EAMS allows promising drugs to be used in clinical practice in parallel with the later stages of the regulatory process • Source: Alamy

More from United Kingdom

More from Europe